IL6 and systemic-onset juvenile idiopathic arthritis: IL-6 is one of the pivotal cytokines in the pathogenesis of SJIA, as prominent IL-6 production has been shown as well as the clinical efficacy of the anti-IL-6 receptor antibody tocilizumab (TCZ) [79, 80].